CAMP4 Therapeutics Corporation(CAMP)

$4.47▲0.01 (0.22%)

CAMP4 Therapeutics Corporation(CAMP)

NASDAQ

$4.47▲0.01 (0.22%)

Overview Intelligence Chart Fundamentals Key Metrics Earnings Growth Analysts Financials Insiders Institutional

Analyst Sentiment

Analysts lean bullish — 63% recommend buying.

Consensus Rating

Buy

24 analysts·High coverage

63%

Rating Distribution

Strong Buy

00%

Buy

1563%

Hold

833%

Sell

14%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 155% higher.

Bear Case

$5.00

+12%

Consensus

$11.40

+155%

Bull Case

$18.00

+303%

Price Range24 analysts

Low

Consensus

High

$5.00

$18.00

Current Target

Current Price

$4.47

Upside to Target

$6.93

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+27.45%

EPS—

FY2028

Rev+589.03%

EPS—

FY2029

Rev+244.24%

EPS—

Earnings Surprises

Recent Analyst Actions

Oct 2, 2025Cantor Fitzgerald

Camp4 Therapeutics initiated with an Overweight at Cantor Fitzgerald

Target:$7.00

+137.3%from $2.95

Nov 5, 2024Leerink Partners

Leerink Partners Starts CAMP4 Therapeutics Corp (CAMP) at Outperform

Target:$17.00

+77.1%from $9.60

Nov 5, 2024Piper Sandler

Piper Sandler Starts CAMP4 Therapeutics Corp (CAMP) at Overweight

Target:$18.00

+87.5%from $9.60

Aug 16, 2022Craig-Hallum

Craig-Hallum upgrades CalAmp to Buy, raises price target to $10

Target:$10.00

+72.4%from $5.80

Jun 24, 2022Goldman Sachs

Goldman Sachs cuts CalAmp EBITDA estimates on lower margin forecasts

Target:$5.00

+1.4%from $4.93

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance